

CARDIO3 BIOSCIENCES APPOINTS DR. WARREN SHERMAN AS CHIEF MEDICAL OFFICER

Mont-Saint-Guibert, Belgium - Cardio3 BioSciences (C3BS) (*Euronext Brussels and Paris: CARD*), a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces today the appointment of Dr. Warren Sherman as Chief Medical Officer, effective as of 1 November 2014. In this new role, Dr. Sherman will leverage his deep expertise in the cardiovascular and cell therapy fields to support the continued development of Cardio3 BioSciences' product pipeline, both in cell therapies and cardiovascular diseases.

Dr. Sherman is a renowned American interventional cardiologist with more than 30 years' experience in the field of cardiology, with a focus in cell-based therapies for treating patients post myocardial infarction and with heart failure.

Before joining Cardio3 BioSciences as Chief Medical Officer, Dr. Sherman was at the Columbia University Medical Center in New York, where he served in a number of capacities, including: Interventional Cardiologist at Columbia University Medical Center/NewYork-Presbyterian Hospital; Director of Stem Cell Research and Regenerative Medicine at the Center for Interventional Vascular Therapy; and Associate Professor of Medicine at Columbia University College of Physicians and Surgeons.

Dr. Sherman is also the founder of the Cardiovascular Research Foundation's [International Conference on Cell Therapy for Cardiovascular Disease](#) (IC3D), which is the foremost meeting for healthcare experts dedicated to the evolving field of cell-based therapies for the repair and regeneration of cardiac and vascular disease. Started in 2004, this annual conference gathers leaders from the international community who present their work, experiences, observations, and opinions on the benefits and unmet challenges of cell-based therapies.

Dr. Sherman received his Bachelors degree from the Massachusetts Institute of Technology, medical degree from the State University of New York Upstate Medical School in Syracuse, and his fellowship training at Oregon Health Sciences University, in Portland, Oregon. He is certified by the American Board of Internal Medicine in Cardiology and Interventional Cardiology, and serves as an advisor to a multitude of government organizations, societies and industries.

Dr. Warren Sherman, CMO of Cardio3 BioSciences, said: *"I am thrilled to be joining Cardio3 BioSciences as Chief Medical Officer at such an exciting time in its clinical development phase. The accomplishments of this young and dynamic company are remarkable, and it is an enormous opportunity for me to be part of the most promising project in the fields of cell therapy and other treatments for cardiovascular diseases."*

Dr. Christian Homsy, CEO of Cardio3 BioSciences, commented: *"We are very pleased to be able to count on Warren Sherman's expertise in clinical application, as well as his renowned scientific*

23 OCTOBER 2014

8:00 AM CET

outreach for the further development of Cardio3 BioSciences' future projects in regenerative therapies and cardiovascular diseases."

*** END ***

For more information, please contact:

Cardio3 BioSciences

Christian Homsy, CEO

Julie Grade, Corporate Communications Manager

For Europe: Citigate Dewe Rogerson

Chris Gardner

For the U.S: Rx Communications Group

Eric Goldman

www.c3bs.com

Tel. : +32 10 39 41 00

jgrade@c3bs.com

Tel : +44 (0) 207 638 9571

Chris.Gardner@citigatedr.co.uk

Tel: +1 917 322 2563

egoldman@RxIR.com

About Cardio3 BioSciences

Cardio3 BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3 BioSciences leverages research collaborations in the US and in Europe with Mayo Clinic and the Cardiovascular Centre Aalst, Belgium.

The Company's lead product candidate C-Cure[®] is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure[®] consists of a patient's own cells that are harvested from the patient's bone marrow and engineered to become new heart muscle. This process is known as Cardiopoiesis.

Cardio3 BioSciences has also developed C-Cath_{ez}[®], the most technologically advanced injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.

Cardio3 BioSciences' shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.

C3BS-CQR-1, C-Cure, C-Cath, Cardio3 BioSciences and the Cardio3 BioSciences and C-Cath logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities.